Key facts
- CiRC Biosciences’s last known valuation is $24.0M (Dec 2020).
- It has raised $39.1M across 2 recorded rounds; the latest was Seed Round ($250K) in Feb 2024.
- Notable investors include Valor Equity Partners, HSC Next, Harmony Biosciences Holdings, Paragon Biosciences, Portal Innovations.
- CiRC Biosciences has filed 2 Form Ds with the SEC, most recently Oct 2024 ($250K sold to 1 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for CiRC Biosciences
Funding rounds
2 roundsAbout CiRC Biosciences
Developer of cell-based therapies designed to offer treatments for serious diseases with high unmet needs, with an initial focus on blindness. The company's therapies bypass the need for stem cells by transforming ordinary skin cells into specialized retinal cells using a cocktail of small molecules, enabling patients suffering from retinal diseases to avail of safer, quicker, and cost-effective treatment.
- Sector
- Healthcare
- HQ
- Chicago, IL, United States
- Founded
- 2019
- Employees
- 6
- Website
- circbiosciences.com/
- Ownership
- Privately Held (backing)
CiRC Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CiRC Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CiRC Biosciences in its N-PORT filings yet. We sweep new filings monthly.